Gcn4p inhibits Rap1p–Esa1p binding. (A) Esa1p binds directly to Rap1p in vitro. GST pull-down analysis using recombinant His6–Rap1, and GST or GST–Esa1 proteins was performed. Proteins input or immunoprecipitated were investigated by western blot or CBB staining. (B) Whole-cell lysates of the BY4741 strain containing indicated combinations of ectopically expressed HA–Esa1 and/or Rap1–FLAG were subjected to co-immunoprecipitation with anti-FLAG or anti-HA antibodies, respectively. Input lysates and precipitated immuno-complexes were examined by western blotting with antibodies against the corresponding epitope tags. (C–E) Association of Esa1p with Rap1p was decreased by Gcn4p under amino-acid starvation. (C) BY4741 cells containing Rap1–FLAG, HA–Esa1 and myc7 or Gcn4-myc7 were harvested after galactose induction. FLAG–Rap1 was immobilized with an anti-FLAG antibody and protein-A agarose, followed by western blotting with antibodies against FLAG, HA and c-myc to detect proteins in input lysates and precipitated fractions. (D) The BY4741 (GCN4) and BY4741Δgcn4 (Δgcn4) strains harbouring the indicated combinations of HA–Esa1 and Rap1–FLAG were cultivated in SRG media for galactose induction, and treated with 10 μg/ml SM or drug vehicle alone. Cells were harvested at the indicated times. Associations of proteins were analysed by co-immunoprecipitation with HA antibody, and input lysates and co-immunoprecipitated proteins were detected with anti-FLAG, anti-HA, anti-Gcn4p and anti-Pgk1p antibodies. (E) GCN4 wild-type and deletion strains harbouring N-terminal TAP-tagged Esa1 (YJK127 and YJK128) were cultivated and treated with 3-AT (80 mM) or drug vehicle alone. After 2 h of incubation, cells were harvested and protein lysates were subjected to pull-down analysis with IgG sepharose beads. Proteins in input lysates and precipitated fractions were examined by western blot with antibodies against Rap1p, TAP and Pgk1p. JS143-7D and YJK101 strains were used as the negative control. (F, G) Competition between Esa1p and Gcn4p for Rap1p binding. (F) A GST pull-down analysis was performed with lysates from cells overexpressed His6–Rap1, GST or GST–Esa1 with increasing amounts of Gcn4–His6. GST or GST–Esa1 loaded onto beads was examined by CBB staining and the level of co-purified His6–Rap1 was detected by western blotting with an anti-His6 antibody. (G) An in vitro binding competition assay was performed as in (A) with some modifications. After the second binding reaction of GST pull-down analysis with GST–Esa1 and His6–Rap1 (500 μg, 5.36 nmol), the beads were washed with 1 ml PBS and an increasing amount of purified Gcn4–His6 (100 μg, 3.11 nmol; 300 μg, 9.34 nmol; 500 μg, 15.56 nmol) or BSA (1 mg, 15.06 nmol) was added into the binding mixture. Following a 1 h incubation at RT, the eluted fraction was separated by centrifugation. His6–Rap1 in elution and bead-bound fractions was examined by western blot with an anti-His6 antibody.